Pasar al contenido principal

Winning combination: biomarkers, immunotherapy, cell death, in that order, or maybe not.

RYC2022-036627-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral blood TCRβ repertoire, IL15, IL2 and soluble ligands for NKG2D activating receptor predict efficacy of immune checkpoint inhibitors in lung cancer

  • Sesma, Andrea
  • Pardo, Julián
  • Isla, Dolores
  • Gálvez Buerba, Eva Mª
  • Gascón, Marta
  • Martínez-Lostao, Luis
  • Moratiel-Pellitero, Alba
  • Paño, José Ramón
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Zapata, María
  • Domingo, María Pilar
  • Esteban, Patricia
  • Sanz-Pamplona, Rebeca
  • Lastra, Rodrigo
  • Ramírez-Labrada, Ariel
4 figures, 5 tables., The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC) without actionable mutations. It has allowed the achievement of durable responses and resulted in significant survival benefits. However, not all patients respond; hence, molecular biomarkers are needed to help us predict which patients will respond. With this objective, a prospective observational study was designed, including a cohort of 55 patients with NSCLC who received ICIs. We studied whether biomarkers such as TCRβ and specific cytokines involved in the regulation of T cell activity were related to the immunotherapy response. In the survival analysis, it was found that patients with higher TCRβ clonality, lower TCRβ evenness, higher TCRβ Shannon diversity and lower TCRβ convergence had higher overall survival (OS) and progression-free survival (PFS). However, no statistically significant association was observed. Regarding cytokines, those patients with higher levels of IL-2 and IL-15 presented statistically significantly shorter OS and PFS, respectively. In fact, in the multivariable analysis, the high IL-15 level increased the risk of death by three times. Although the sample size was small and more studies are needed to confirm our results, our study reveals promising markers of responses to ICIs., Work in the JP lab is funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_20R), Grant PID2020-113963RB-I00 by MICIN/AEI, CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, CB21/13/00087), Grant PTA2019-016739-I funded by MCIN/AEI/10.13039/501100011033 to PD, Instituto de Salud Carlos III, Aspanoa and Carrera de la mujer de Monzón. Grant PID2020-113963RB-I00 by MICIN/AEI to EMGB. Contrato Ramón y Cajal RYC2022-036627-I (AR-L). Bristol Myers Squibb. Roche Farma S.A., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

CAR immunotherapy for the treatment of infectious diseases: a systematic review

  • Morte-Romea, Elena
  • Pesini, Cecilia
  • Pellejero-Sagastizábal, Galadriel
  • Letona-Giménez, Santiago
  • Martínez-Lostao, Luis
  • Loscos Aranda, Silvia
  • Toyas, Carla
  • Redrado, Sergio
  • Dolader-Ballesteros, Elena
  • Arias, Maykel
  • Galvez, Eva M.
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño-Pardo, Jose Ramón
  • Ramírez-Labrada, Ariel
Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Multiparametric in vitro and in vivo analysis of the safety profile of self-assembling peptides

  • Ramirez-Labrada, Ariel
  • Santiago, Llipsy
  • Pesini, Cecilia
  • Arrieta, Marta
  • Arias, Maykel
  • Calvo Pérez, Adanays
  • Ciulla, Maria Gessica
  • Forouharshad, Mahdi
  • Pardo, Julian
  • Gálvez, Eva M.
  • Gelain, Fabrizio
Self-assembling peptides (SAPs) have gained significant attention in biomedicine because of their unique properties and ability to undergo molecular self-assembly driven by non-covalent interactions. By manipulating their composition and structure, SAPs can form well-ordered nanostructures with enhanced selectivity, stability and biocompatibility. SAPs offer advantages such as high chemical and biological diversity and the potential for functionalization. However, studies concerning its potentially toxic effects are very scarce, a limitation that compromises its potential translation to humans. This study investigates the potentially toxic effects of six different SAP formulations composed of natural amino acids designed for nervous tissue engineering and amenable to ready cross-linking boosting their biomechanical properties. All methods were performed in accordance with the relevant guidelines and regulations. A wound-healing assay was performed to evaluate how SAPs modify cell migration. The results in vitro demonstrated that SAPs did not induce genotoxicity neither skin sensitization. In vivo, SAPs were well-tolerated without any signs of acute systemic toxicity. Interestingly, SAPs were found to promote the migration of endothelial, macrophage, fibroblast, and neuronal-like cells in vitro, supporting a high potential for tissue regeneration. These findings contribute to the development and translation of SAP-based biomaterials for biomedical applications.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  • Pesini, Cecilia
  • Artal, Laura
  • Paúl Bernal, Jorge
  • Sánchez Martinez, Diego
  • Pardo, Julián
  • Ramírez-Labrada, Ariel
Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Peripheral Blood TCRß Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer

  • Sesma, Andrea
  • Pardo, Julian
  • Isla, Dolores
  • M. Gálvez, Eva
  • Gascón-Ruiz, Marta
  • Martínez-Lostao, Luis
  • Moratiel, Alba
  • Paño-Pardo, J. Ramón
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Zapata-García, María
  • Domingo, María Pilar
  • Esteban, Patricia
  • Sanz Pamplona, Rebeca
  • Lastra, Rodrigo
  • Ramírez-Labrada, Ariel
The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC) without actionable mutations. It has allowed the achievement of durable responses and resulted in significant survival benefits. However, not all patients respond; hence, molecular biomarkers are needed to help us predict which patients will respond. With this objective, a prospective observational study was designed, including a cohort of 55 patients with NSCLC who received ICIs. We studied whether biomarkers such as TCRβ and specific cytokines involved in the regulation of T cell activity were related to the immunotherapy response. In the survival analysis, it was found that patients with higher TCRβ clonality, lower TCRβ evenness, higher TCRβ Shannon diversity and lower TCRβ convergence had higher overall survival (OS) and progression-free survival (PFS). However, no statistically significant association was observed. Regarding cytokines, those patients with higher levels of IL-2 and IL-15 presented statistically significantly shorter OS and PFS, respectively. In fact, in the multivariable analysis, the high IL-15 level increased the risk of death by three times. Although the sample size was small and more studies are needed to confirm our results, our study reveals promising markers of responses to ICIs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms

  • Pesini, Cecilia
  • Gil-Bellido, Mario
  • Millán, Lorena S.
  • Oñate, Carmen
  • Calvo-Pérez, Adanays
  • Santiago, Llipsy
  • Iglesias, Eldris
  • Bernal, Jorge Paúl
  • Araujo-Voces, Miguel
  • Paz Artigas, Laura
  • García-Martínez, Laura
  • Roig, Francisco J
  • Movilla Meno, Nieves
  • Garcia-Aznar, José Manuel
  • Menéndez-Jandula, Bárbara
  • Olave, María Teresa
  • Azaceta Reinares, Gemma
  • Garrote, Marta
  • Alvarez-Larrán, Alberto
  • Gálvez, Eva M
  • Sánchez Martínez, Diego
  • Arias, Maykel A
  • Pardo, Julian
  • Ramirez-Labrada, Ariel
Background The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy. Methods Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted. Results Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance. Conclusions This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs.